Monte Rosa Therapeutics, Inc. GLUE

Rank #2341 · Nasdaq · $0.9B market cap

Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.

Score

23.5

P/E

-12.5

P/B

5.07

ROE

-40.6%

Op. Margin

-107.3%

Debt Ratio

120%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -12.5x, P/B 5.07x. Ranks in the top 74% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -40.6%. Ranks in the top 88% of the universe.

Safety ★★★☆☆

Average

Debt ratio 120%. Ranks in the top 46% of the universe.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2021	–	$-0.0B	$-0.0B	$0.0B	–	62
2022	–	$-0.1B	$-0.1B	$-0.0B	–	-39
2023	–	$-0.1B	$-0.1B	$0.3B	–	20
2024	$0.0B	$-0.1B	$-0.1B	$0.3B	–	46
2025	$0.1B	$-0.1B	$-0.1B	$0.2B	-107.3	120